The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency

HIV eradication is hindered by the existence of latent HIV reservoirs in CD4+ T cells. Therapeutic strategies targeting latent cells are required to achieve a functional cure, however the study of latently infected cells from HIV infected persons is extremely challenging due to the lack of biomarkers that uniquely characterize them. In this study, the dual reporter virus HIVGKO was used to investigate latency establishment and maintenance in lymphoid-derived CD4+ T cells. Single cell technologies to evaluate protein expression, host gene expression, and HIV transcript expression were integrated to identify and analyze latently infected cells. FDA-approved, JAK1/2 inhibitors were tested in this system as a potential therapeutic strategy to target the latent reservoir. Latent and productively infected tonsillar CD4+ T cells displayed similar activation profiles as measured by expression of CD69, CD25, and HLADR, however latent cells showed higher CXCR5 expression 3 days post-infection. Single cell analysis revealed a small set of genes, including HIST1-related genes and the inflammatory cytokine, IL32, that were upregulated in latent compared to uninfected and productively infected cells suggesting a role for these molecular pathways in persistent HIV infection. In vitro treatment of HIV-infected CD4+ T cells with physiological concentrations of JAK1/2 inhibitors, ruxolitinib and baricitinib, used in clinical settings to target inflammation, reduced latent and productive infection events when added 24 hr after infection and blocked HIV reactivation from latent cells. Our methods using an established model of HIV latency and lymphoid-derived cells shed light on the biology of latency in a crucial anatomical site for HIV persistence and provides key insights about repurposing baricitinib or ruxolitinib to target the HIV reservoir.

[1]  M. Lederman,et al.  Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Siliciano,et al.  Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques , 2021, Nature Communications.

[3]  D. Hazuda,et al.  IL-10 driven memory T cell survival and Tfh differentiation promote HIV persistence , 2021, bioRxiv.

[4]  R. B. Jones,et al.  The Intact Noninducible Latent HIV-1 Reservoir Is Established in an In Vitro Primary TCM Cell Model of Latency , 2021, Journal of Virology.

[5]  R. Siliciano,et al.  Recommendations for measuring HIV reservoir size in cure-directed clinical trials , 2020, Nature medicine.

[6]  W. Greene,et al.  Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir , 2020, eLife.

[7]  W. Greene,et al.  Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection , 2020, PLoS pathogens.

[8]  J. Lifson,et al.  CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption , 2020, Nature Medicine.

[9]  Jerome H. Kim,et al.  Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection , 2020, Science Translational Medicine.

[10]  Gérémy Sannier,et al.  Single-Cell Technologies Applied to HIV-1 Research: Reaching Maturity , 2020, Frontiers in Microbiology.

[11]  S. Gianella,et al.  HIV persists throughout deep tissues with repopulation from multiple anatomical sources. , 2020, The Journal of clinical investigation.

[12]  S. Trottier,et al.  Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. , 2019, Journal of acquired immune deficiency syndromes.

[13]  S. Lewin,et al.  Limitations of dual‐fluorescent HIV reporter viruses in a model of pre‐activation latency , 2019, Journal of the International AIDS Society.

[14]  B. Lloveras,et al.  Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa , 2019, Nature Communications.

[15]  S. Pallikkuth,et al.  Implications of Immune Checkpoint Expression during Aging for HIV-infected People on ART. , 2019, AIDS research and human retroviruses.

[16]  R. Schinazi,et al.  Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro , 2019, Journal of Neuroinflammation.

[17]  B. Berkhout,et al.  The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like , 2019, Front. Immunol..

[18]  C. Scagnolari,et al.  Increased expression of IL-32 correlates with IFN-γ, Th1 and Tc1 in virologically suppressed HIV-1-infected patients. , 2019, Cytokine.

[19]  E. Rakasz,et al.  Low levels of SIV-specific CD8+ T cells in germinal centers characterizes acute SIV infection , 2019, PLoS pathogens.

[20]  Suha M. Saleh,et al.  HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal , 2019, AIDS.

[21]  R. Siliciano,et al.  A novel quantitative approach for measuring the reservoir of latent HIV-1 proviruses , 2019, Nature.

[22]  S. Pallikkuth,et al.  Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy , 2019 .

[23]  M. Robb,et al.  Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy , 2018, Nature Communications.

[24]  B. Haynes,et al.  Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. , 2018, Cell reports.

[25]  L. Picker,et al.  Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound , 2018, Nature Medicine.

[26]  R. Koup,et al.  Altered immune cell follicular dynamics in HIV infection following influenza vaccination , 2018, The Journal of clinical investigation.

[27]  Eric Verdin,et al.  Anti‐apoptotic Protein BIRC5 Maintains Survival of HIV‐1‐Infected CD4+ T Cells , 2018, Immunity.

[28]  E. Wherry,et al.  Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue , 2018, Science Immunology.

[29]  W. Greene,et al.  Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells , 2018, eLife.

[30]  N. Beerenwinkel,et al.  Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells. , 2018, Cell reports.

[31]  B. Haynes,et al.  Single cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency , 2018, bioRxiv.

[32]  Emily B Hanhauser,et al.  Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30 , 2018, PLoS pathogens.

[33]  J. Routy,et al.  Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors , 2017, PLoS pathogens.

[34]  P. Benaroch,et al.  Myeloid Cell Interaction with HIV: A Complex Relationship , 2017, Front. Immunol..

[35]  J. Lifson,et al.  Defining total-body AIDS-virus burden with implications for curative strategies , 2017, Nature Medicine.

[36]  Gourab Mukherjee,et al.  Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. , 2017, Cell reports.

[37]  B. Walker,et al.  HIV Infection of Macrophages: Implications for Pathogenesis and Cure , 2017, Pathogens & immunity.

[38]  Y. Lévy,et al.  CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.

[39]  Youfang Cao,et al.  HIV persistence in tissue macrophages of humanized myeloid only mice during antiretroviral therapy , 2017, Nature Medicine.

[40]  P. Palma,et al.  Induction of IL21 in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort , 2017, The Journal of Immunology.

[41]  Michael Y. Gerner,et al.  Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies , 2017, Science Translational Medicine.

[42]  K. Anastos,et al.  Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus–Herpes Simplex Virus Coinfection , 2016, The Journal of infectious diseases.

[43]  Eric Verdin,et al.  The mTOR Complex Controls HIV Latency. , 2016, Cell host & microbe.

[44]  S. Lewin,et al.  CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART , 2016, PLoS pathogens.

[45]  M. Lederman,et al.  IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. , 2016, The Journal of clinical investigation.

[46]  J. Lifson,et al.  Defining HIV and SIV Reservoirs in Lymphoid Tissues , 2016, Pathogens & immunity.

[47]  G. Pantaleo,et al.  PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals , 2016, Nature Medicine.

[48]  Suha M. Saleh,et al.  LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV , 2016, EBioMedicine.

[49]  M. Fischl,et al.  Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy , 2015, Journal of Virology.

[50]  J. Church B Cell Follicle Sanctuary Permits Persistent Productive Simian Immunodeficiency Virus Infection in Elite Controllers , 2015, Pediatrics.

[51]  W. Greene,et al.  Blood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection. , 2015, Cell host & microbe.

[52]  E. Verdin,et al.  HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells , 2015, PLoS pathogens.

[53]  L. Picker,et al.  A B cell follicle sanctuary permits persistent productive SIV infection in elite controllers , 2014, Nature Medicine.

[54]  Debbie,et al.  Blood-Derived CD 4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection Graphical , 2015 .

[55]  Timothy J. Laurent,et al.  Dual-color HIV reporters trace a population of latently infected cells and enable their purification. , 2013, Virology.

[56]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[57]  M. Lederman,et al.  Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. , 2013, The Journal of infectious diseases.

[58]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[59]  G. Pantaleo,et al.  Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.

[60]  F. Bushman,et al.  Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency , 2012, PLoS pathogens.

[61]  G. Boucher,et al.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton , 2010, Proceedings of the National Academy of Sciences.

[62]  J. Karn,et al.  Establishment of HIV Latency in Primary CD4+ Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction , 2010, Journal of Virology.

[63]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[64]  Alberto Bosque,et al.  Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. , 2009, Blood.

[65]  T. Schacker The role of secondary lymphatic tissue in immune deficiency of HIV infection , 2008, AIDS.

[66]  C. Dinarello,et al.  Endogenous IL-32 Controls Cytokine and HIV-1 Production1 , 2008, The Journal of Immunology.

[67]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[68]  Suha M. Saleh,et al.  CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. , 2007, Blood.

[69]  J. Orenstein,et al.  Regulation of the tonsil cytokine milieu favors HIV susceptibility , 2006, Journal of leukocyte biology.

[70]  Angelika Pedal,et al.  SIRT1 Regulates HIV Transcription via Tat Deacetylation , 2005, PLoS biology.

[71]  S. Zeichner,et al.  Host Cell Gene Expression during Human Immunodeficiency Virus Type 1 Latency and Reactivation and Effects of Targeting Genes That Are Differentially Expressed in Viral Latency , 2004, Journal of Virology.

[72]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[73]  A. Fauci,et al.  Lymphoid organs function as major reservoirs for human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.